GlassScriptPhysician profile
Ahmad Kadhim
NPI 1386892479
$155,323.57
in general payments reported to CMS, 2019-2025
36 companies · $61K in 2025
The $61K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,358 · 2020: $526 · 2021: $14K · 2022: $1,019 · 2023: $1,997 · 2024: $69K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Travel and Lodging: $15K · Food and Beverage: $10K · Education: $27.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,476.86 |
| Travel and Lodging | $15,174.04 |
| Food and Beverage | $10,144.02 |
| Education | $27.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $75,891.04 | 2019-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $27,453.67 | 2024-2025 | Voquezna |
| Pfizer INC. | $24,287.60 | 2019-2025 | |
| Abbvie INC. | $14,933.49 | 2019-2025 | |
| Allergan, INC. | $7,705.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $921.02 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.82 | 2020-2025 | Trulance, Xifaxan, Relistor |
| Lilly USA, LLC | $326.30 | 2025 | Omvoh, Mounjaro, Zepbound |
| Ferring Pharmaceuticals INC. | $289.73 | 2022-2025 | Rebyota, Cimzia |
| Gilead Sciences, INC. | $265.78 | 2021-2024 | Livdelzi |
| Janssen Scientific Affairs, LLC | $242.65 | 2023-2025 | Stelara, Tremfya |
| Pentax of America, INC. | $225.50 | 2023-2025 | Pentax Medical, Inspira, C2 Cryoballoon |
| Sanofi-Aventis U.S. LLC | $212.30 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $200.90 | 2023 | Fujifilm |
| Novo Nordisk INC | $182.37 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $164.84 | 2022-2025 | |
| Neurelis, INC. | $149.97 | 2021 | |
| Mallinckrodt Hospital Products INC. | $129.03 | 2022-2024 | Terlivaz |
| Ardelyx, INC. | $125.55 | 2022-2025 | Ibsrela |
| Lucid Diagnostics INC. | $110.60 | 2022 | |
| Braintree Laboratories, INC. | $105.65 | 2019-2021 | |
| Erbe USA INC | $100.00 | 2025 | Vio3 |
| E.R. Squibb & Sons, L.L.C. | $96.79 | 2023 | Zeposia |
| Ethicon US, LLC | $96.06 | 2019 | |
| Boston Scientific Corporation | $84.59 | 2025 | Exalt Model D |
| Regeneron Healthcare Solutions, INC. | $77.64 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $57.68 | 2019 | |
| Ucb, INC. | $54.95 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $51.28 | 2021-2022 | |
| Qol Medical, LLC | $49.63 | 2022-2024 | Sucraid |
| Celgene Corporation | $47.47 | 2021-2022 | |
| Madrigal Pharmaceuticals | $33.03 | 2025 | Rezdiffra |
| Rayner Intraocular Lenses Limited | $27.26 | 2025 | Omidria |
| Daiichi Sankyo INC. | $26.99 | 2024 | Injectafer |
| Alfasigma USA, INC. | $17.37 | 2020 | |
| Merck Sharp & Dohme LLC | $14.79 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Kadhim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.